Patients Pharma 2030: Will payers fund more preventive care programme... Preventive care programmes are key to better health outcomes, but several factors are limiting their uptake.
News BioMarin snaps up Alesta's lead asset for $275M BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
